To validate the impact of the CTNNB1 mutation on the tumour microenvironment during chemoimmunotherapy, we further assessed the tumour immune infiltration status using evidence from CD8+ T cells and PD‐L1 staining in patients with the CTNNB1 mutation via mIF (Figure 4C, D). The gene discussed is CD8A; the disease is neoplasm.